• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本 2011 年骨质疏松症防治指南——执行摘要。

Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary.

机构信息

Japan Osteoporosis Foundation, Tokyo, Japan.

出版信息

Arch Osteoporos. 2012;7(1):3-20. doi: 10.1007/s11657-012-0109-9.

DOI:10.1007/s11657-012-0109-9
PMID:23203733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3517709/
Abstract

INTRODUCTION

In 1998, the first Japanese practice guidelines on osteoporosis was published. It has been updated several times, with the most recent being the full-scale 2011 edition and its abridged edition. The present guidelines provide information for the managements of primary osteoporosis in postmenopausal women and men over 50 years old, a summary of the evidence for the treatment of secondary osteoporosis, and a summary of the evidence for the prevention of osteoporosis in younger people.

METHOD

The present Executive Summary is primarily based on the content of the 2011 Japanese abridged edition. One of the key changes is revision of the criteria for initiation of pharmacological treatment, along with an introduction of the fracture risk factors used in FRAX®. Key figures and tables were selected from the Japanese abridged edition and a reference list was added.

RESULT AND CONCLUSIONS

The essential points of the Japanese practice guidelines on osteoporosis were translated into English for the first time. It is hoped that the content of the guidelines becomes known throughout the world.

摘要

简介

1998 年,日本发布了第一版骨质疏松症实践指南。该指南已经过多次更新,最近一次是 2011 年全面版及其精简版。本指南为绝经后妇女和 50 岁以上男性原发性骨质疏松症的管理提供了信息,总结了治疗继发性骨质疏松症的证据,并总结了预防年轻人骨质疏松症的证据。

方法

本执行摘要主要基于 2011 年日本精简版的内容。一个关键的变化是修订了开始药物治疗的标准,并引入了 FRAX®中使用的骨折风险因素。从日本精简版中选择了关键的数字和表格,并添加了参考列表。

结果与结论

日本骨质疏松症实践指南的要点首次被翻译成英文。希望指南的内容能够在全世界范围内得到了解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/fdc107d984dd/11657_2012_109_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/a0d65ee50fe2/11657_2012_109_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/759a469878d1/11657_2012_109_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/2032ecca92c8/11657_2012_109_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/ef44340d7658/11657_2012_109_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/4a0077a20494/11657_2012_109_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/8ac9a3cea869/11657_2012_109_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/76a5b7d05bb9/11657_2012_109_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/efb5fd568547/11657_2012_109_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/94795b628680/11657_2012_109_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/b8cd62b77211/11657_2012_109_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/c953a159889d/11657_2012_109_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/7c030310fcbf/11657_2012_109_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/f21f061545b2/11657_2012_109_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/fdc107d984dd/11657_2012_109_Fig14_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/a0d65ee50fe2/11657_2012_109_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/759a469878d1/11657_2012_109_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/2032ecca92c8/11657_2012_109_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/ef44340d7658/11657_2012_109_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/4a0077a20494/11657_2012_109_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/8ac9a3cea869/11657_2012_109_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/76a5b7d05bb9/11657_2012_109_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/efb5fd568547/11657_2012_109_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/94795b628680/11657_2012_109_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/b8cd62b77211/11657_2012_109_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/c953a159889d/11657_2012_109_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/7c030310fcbf/11657_2012_109_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/f21f061545b2/11657_2012_109_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5053/3517709/fdc107d984dd/11657_2012_109_Fig14_HTML.jpg

相似文献

1
Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary.日本 2011 年骨质疏松症防治指南——执行摘要。
Arch Osteoporos. 2012;7(1):3-20. doi: 10.1007/s11657-012-0109-9.
2
[Revised osteoporosis diagnostic criteria and Japanese practice guideline on osteoporosis].[修订后的骨质疏松症诊断标准及日本骨质疏松症诊疗指南]
Clin Calcium. 2014 Jan;24(1):11-8.
3
[Japanese Guidelines for the Prevention and Treatment of Osteoporosis (2006 Edition) and its significance].[日本骨质疏松症防治指南(2006年版)及其意义]
Nihon Rinsho. 2007 Nov 28;65 Suppl 9:29-34.
4
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Guideline for prevention and treatment of osteoporosis update].[骨骼与钙更新;代谢性骨病的诊断与治疗更新。骨质疏松症防治指南更新]
Clin Calcium. 2011 Dec;21(12):123-43.
5
[Criteria for initiation of pharmacological treatment by Japanese 2011 guidelines for prevention and treatment of osteoporosis].[日本2011年骨质疏松症防治指南中药物治疗起始标准]
Clin Calcium. 2014 Mar;24(3):339-47.
6
Osteoporosis and treatments in Japan: management for preventing subsequent fractures.日本的骨质疏松症与治疗:预防后续骨折的管理。
J Bone Miner Metab. 2013 Jul;31(4):367-80. doi: 10.1007/s00774-013-0444-y. Epub 2013 Mar 28.
7
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.绝对骨折风险评估对美国骨质疏松症诊疗指南的影响。
Osteoporos Int. 2008 Apr;19(4):449-58. doi: 10.1007/s00198-008-0559-5. Epub 2008 Feb 22.
8
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.采用FRAX工具进行骨质疏松症管理的病例发现——英国的评估与干预阈值
Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1. Epub 2008 Aug 28.
9
[Absolute risk for fracture and WHO guideline. Fracture risk assessments recommended by World Health Organization and Japanese guidelines for prevention and treatment of osteoporosis 2006].[骨折的绝对风险与世界卫生组织指南。世界卫生组织推荐的骨折风险评估以及《2006年日本骨质疏松症防治指南》]
Clin Calcium. 2007 Jul;17(7):1022-8.
10
The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice.骨折风险评估工具(FRAX®):临床实践中的应用。
J Womens Health (Larchmt). 2011 Apr;20(4):525-31. doi: 10.1089/jwh.2010.2294. Epub 2011 Mar 25.

引用本文的文献

1
The determinants of self-care behaviors and calcium-vitamin D intake in elderly women: a comparative study of osteoporosis and healthy counterparts.老年女性自我护理行为及钙-维生素D摄入量的决定因素:骨质疏松症患者与健康对照者的比较研究
Sci Rep. 2025 Jul 26;15(1):27290. doi: 10.1038/s41598-025-12755-4.
2
Vitamin K: Metabolism, Genetic Influences, and Chronic Disease Outcomes.维生素K:代谢、遗传影响及慢性病结局
Food Sci Nutr. 2025 Jun 17;13(6):e70431. doi: 10.1002/fsn3.70431. eCollection 2025 Jun.
3
The prevention of osteoporotic vertebral fractures in eastern and in western countries.

本文引用的文献

1
Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition).骨代谢标志物在骨质疏松症诊断和治疗中的临床应用指南(2012 年版)。
J Bone Miner Metab. 2013 Jan;31(1):1-15. doi: 10.1007/s00774-012-0392-y. Epub 2012 Nov 10.
2
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.一种新型活性维生素 D3 类似物,依降钙素,可预防骨质疏松性骨折的风险 - 一项随机、活性对照、双盲研究。
Bone. 2011 Oct;49(4):605-12. doi: 10.1016/j.bone.2011.07.011. Epub 2011 Jul 19.
3
Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
东西方国家骨质疏松性椎体骨折的预防
Bone Rep. 2025 May 15;25:101851. doi: 10.1016/j.bonr.2025.101851. eCollection 2025 Jun.
4
Dietary menaquinone-9 supplementation does not influence bone tissue quality or bone mineral density during skeletal development in mice.膳食补充甲基萘醌-9对小鼠骨骼发育过程中的骨组织质量或骨矿物质密度没有影响。
JBMR Plus. 2025 Apr 10;9(6):ziaf059. doi: 10.1093/jbmrpl/ziaf059. eCollection 2025 Jun.
5
The usefulness of different imaging modalities in mandibular osteonecrosis and osteomyelitis diagnosis.不同成像方式在下颌骨坏死和骨髓炎诊断中的作用。
Sci Rep. 2025 Apr 10;15(1):12272. doi: 10.1038/s41598-025-96910-x.
6
Difference in Bone Density in Young Women With Normal Occlusion and Malocclusion.正常咬合与错颌的年轻女性骨密度差异。
Cureus. 2025 Feb 26;17(2):e79731. doi: 10.7759/cureus.79731. eCollection 2025 Feb.
7
Association Between the Bone Density of Alveolar and General Skeletal Bones in the Young.年轻人牙槽骨与全身骨骼骨密度之间的关联
Cureus. 2025 Feb 6;17(2):e78643. doi: 10.7759/cureus.78643. eCollection 2025 Feb.
8
Dietary Menaquinone-9 Supplementation Does Not Influence Bone Tissue Quality or Bone Mineral Density in Mice.膳食补充甲基萘醌-9对小鼠骨组织质量或骨密度无影响。
bioRxiv. 2025 Feb 2:2025.01.29.635567. doi: 10.1101/2025.01.29.635567.
9
Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study.绝经后骨质疏松症患者从双膦酸盐类药物转换为地诺单抗、特立帕肽或罗莫单抗的影响:一项病例对照研究。
Osteoporos Int. 2025 Mar;36(3):531-538. doi: 10.1007/s00198-025-07386-4. Epub 2025 Jan 16.
10
Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study.地舒单抗与罗莫佐单抗治疗男性骨质疏松症的比较:一项回顾性队列研究。
Sci Rep. 2024 Oct 1;14(1):22785. doi: 10.1038/s41598-024-73398-5.
阿仑膦酸钠联合阿尔法骨化醇治疗骨折高风险骨质疏松症患者的效果:日本骨质疏松症干预试验(JOINT)-02。
Curr Med Res Opin. 2011 Jun;27(6):1273-84. doi: 10.1185/03007995.2011.580341. Epub 2011 May 10.
4
Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends.日本髋部骨折发病率:2007年新增患者估计数及20年趋势
Arch Osteoporos. 2009 Dec;4(1-2):71-77. doi: 10.1007/s11657-009-0031-y. Epub 2009 Oct 2.
5
Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study.日本男性和女性膝关节骨关节炎、腰椎病和骨质疏松症的患病率:骨关节炎/骨质疏松症与残疾研究
J Bone Miner Metab. 2009;27(5):620-8. doi: 10.1007/s00774-009-0080-8. Epub 2009 Jul 1.
6
Age-related distribution of bone and skeletal parameters in 1,322 Japanese young women.1322 名日本年轻女性的骨骼和骨骼参数与年龄相关的分布。
J Bone Miner Metab. 2009;27(6):698-704. doi: 10.1007/s00774-009-0094-2. Epub 2009 May 12.
7
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.米诺膦酸盐与阿仑膦酸盐治疗绝经后骨质疏松症女性的双盲头对头试验。
Bone. 2009 Jun;44(6):1078-84. doi: 10.1016/j.bone.2009.02.016. Epub 2009 Mar 2.
8
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.每日口服米诺膦酸对日本绝经后骨质疏松症女性椎体骨折的影响:一项随机安慰剂对照双盲研究。
Osteoporos Int. 2009 Aug;20(8):1429-37. doi: 10.1007/s00198-008-0816-7. Epub 2008 Dec 20.
9
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.系统评价:预防骨密度低或患骨质疏松症的男性和女性骨折的治疗方法的比较效果
Ann Intern Med. 2008 Feb 5;148(3):197-213. doi: 10.7326/0003-4819-148-3-200802050-00198. Epub 2007 Dec 17.
10
Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.维生素K与骨折预防:随机对照试验的系统评价与荟萃分析
Arch Intern Med. 2006 Jun 26;166(12):1256-61. doi: 10.1001/archinte.166.12.1256.